TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 65 years on the day of vaccination~* Informed consent form signed and dated~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination), or planned participation during each year of the trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure (Note: Concomitant participation in an observational trial is acceptable)~* Vaccination against influenza in the 6 months preceding the trial vaccination~* Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a history of a life-threatening reaction to Fluzone High-Dose or Fluzone vaccine or to a vaccine containing any of the same substances~* Personal history of Guillain-Barré Syndrome~* Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures~* Thrombocytopenia contraindicating intramuscular (IM) vaccination, as judged by the investigator~* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination, as judged by the investigator~* Current alcohol abuse or drug addiction~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study~* Moderate or severe acute illness with or without fever (oral temperature \> 99.0ºF \[\> 37.2ºC\]). If this contraindication exists, vaccination will be deferred until the individual has been medically stable and/or afebrile (temperature ≤ 99.0 ºF \[≤ 37.2ºC\]) for at least 24 hours~* Signs and symptoms of an acute infectious respiratory illness. If this exists, vaccination will be deferred until the symptoms resolve.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High Dose Trivalent Inactivated Influenza Vaccine (Type: EXPERIMENTAL): Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
- Trivalent Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): Participants will receive an injection of the Trivalent Inactivated Influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Overactive Bladder Syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 50 years of age~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Patient requires extraction of 2 or more third molars~* Patient must be willing to stay at the study site for at least 8 hours after dosing of the study drug~Exclusion Criteria:~* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test~* Patient has taken another investigational drug within 30 days prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Indomethacin Test (lower dose) (Type: EXPERIMENTAL): None
- Indomethacin Test (upper dose) (Type: EXPERIMENTAL): Single dose
- Celecoxib 400 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Troponin I Release After High Diuretic Doses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* signs/symptoms of heart failure;~* New York Heart Association (NYHA) functional Class III or IV on admission due to an exacerbation of symptoms with at least 1 class deterioration;~* evidence of systolic dysfunction on echocardiographic examination on admission (EF\<45%);~* BNP levels on admission \> 100pg/mL~Exclusion Criteria:~* NYHA class \< III on admission or without a NYHA class improvement on discharge;~* acute coronary syndrome,~* pulmonary thromboembolism,~* cardiac tamponade,~* pericarditis,~* renal insufficiency (serum creatinine \<2,5 mg/dL, BUN \<60 mg/dL) or those on dialysis;~* chronic liver disease,~* pleuro-pneumonia,~* blood and autoimmune diseases,~* concomitant other important co-morbidity,~* cerebral vascular disease,~* dementia,~* cancer,~* uncompensated diabetes,~* took non-steroid anti-inflammatory drugs (NSAID)~* declining to provide informed consent,~* patients requiring pacemaker implantation and those with issues of excessive alcohol consumption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- High doses furosemide (Type: PLACEBO_COMPARATOR): administration of furosemide alone
- HSS plus furosemide (Type: EXPERIMENTAL): administration of hypertonic saline solution plus high doses of furosemide bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of colon~  * Stage III (T1-4, N1-3, M0) disease~* Has undergone surgical resection of the tumor within the past 8 weeks~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Able to take medications orally~* WBC ≥ 3,500/mm³ and \< 12,000/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9.0 g/dL~* Total bilirubin ≤ 2.0 mg/dL~* AST/ALT ≤ 100 IU/L~* Creatinine ≤ 1.2 mg/dL~* No other active malignancies~* Must have none of the following comorbidities:~  * Severe postoperative complications~ * Uncontrollable diabetes mellitus~ * Uncontrollable hypertension~ * Myocardial infraction within 6 months~ * Unstable angina pectoris~ * Hepatocirrhosis~ * Interstitial pneumonia, pulmonary fibrosis, or severe emphysema~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for colon cancer~* No concurrent radiotherapy~* No concurrent biological response modifiers

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- tegafur-gimeracil-oteracil potassium (Type: EXPERIMENTAL): Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
- tegafur-uracil and folinate calcium (Type: ACTIVE_COMPARATOR): Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 35 years~* Male~* Healthy~Exclusion Criteria:~* Use of any medication.~* History of allergic reaction to dipyridamole~* Bleeding disorder.~* Smoking.~* Previous spontaneous vagal collapse.~* History, signs or symptoms of cardiovascular disease.~* Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.~* Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90).~* Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50).~* Renal impairment (defined as plasma creatinin \>120 μmol/l).~* Liver enzyme abnormalities or positive hepatitis serology.~* Positive HIV serology or any other obvious disease associated with immune deficiency.~* Febrile illness in the week before the LPS challenge.~* Participation in another drug trial or donation of blood 3 months prior to the planned LPS challenge.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Endotoxemia placebo (Type: PLACEBO_COMPARATOR): Endotoxin combined with placebo
- Endotoxemia Dipyridamole (Type: EXPERIMENTAL): Endotoxin combined with Dipyridamol treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months to 17 years of age~* Moderate to severe atopic dermatitis~Exclusion Criteria:~* Use of cephalexin or other antibiotic in last 6 weeks~* Allergy to cephalosporins

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
- Placebo (Type: PLACEBO_COMPARATOR): Intranasal petrolatum ointment treatment and plain water baths

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis C (CHC), genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) according to standard of care and in line with the current local label~* If RBV was co-administered with the ABBVIE REGIMEN, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)~* Participants had to voluntarily sign and date an informed consent form prior to inclusion into the study~* Participants must not have participated or intended to participate in a concurrent interventional therapeutic trial~Exclusion Criteria:~• None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Participants with HCV genotype 1 or 4 (Type: None): Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alice PDx User/Validation Extended Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must call into a sleep lab or be referred to a sleep lab for a diagnostic polysomnogram~* Able to follow directions~* Able to provide informed consent~Exclusion Criteria:~* Participants requiring supplemental oxygen therapy~* History of having a previous sleep study/polysomnogram performed~* Current positive airway pressure (PAP) users~* Unable or unwilling to perform a polysomnogram

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alice PDx with only written instructions (Type: OTHER): Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
- Alice PDx with written and verbal instructions (Type: OTHER): Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* normal subjects who are age 18-65~* generally healthy~* non-childbearing potential females or those using birth control~Exclusion Criteria:~* history of significant GI disease~* any significant medical illness~* history of hypersensitivity, allergy or intolerance to omeprazole, lansoprazole or other proton pump inhibitors~* currently using GI medications~* GI disorder or surgery leading to impaired drug absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Prilosec OTC
- B (Type: ACTIVE_COMPARATOR): Prevacid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: • Patients aged 6 months-10 years.~* mono-infection with P. falciparum detected by microscopy;~* parasitaemia of 250 - 200,000/μl asexual forms;~* presence of axillary temperature ≥37.5 °C or history of fever during the past 24 hours~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the parents or guardians of children.~Exclusion Criteria:~* presence of general danger signs in children aged 6 months-10 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);~* weight under 5 Kg~* mixed or mono-infection with another Plasmodium species detected by microscopy;~* presence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm);~* presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* regular medication, which may interfere with antimalarial pharmacokinetics;~* history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 to 75 years old, with type 2 diabetes with inadequate glycemic control~* Subjects receiving insulin and metformin and/or a thiazolidinedione~* Body Mass Index \<=45.0 kg/m2~* Serum creatinine \<1.5 mg/dL for men or \<1.4 mg/dL for women~* No overt proteinuria (in subjects with a microalbumin/creatinine ratio ≥300 mg/g, the 24-hour urinary excretion of total protein must be \<3 g/24 hrs)~Exclusion Criteria:~* History of type 1 diabetes~* AST and/or ALT \>2.5 times the upper limit of normal~* Creatinine kinase ≥3 times the upper limit of normal~* Symptoms of severely uncontrolled diabetes~* History of hypoglycemic unawareness~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 20 mg
- Cohort 2 - Arm 1 (Type: EXPERIMENTAL): 10 mg
- Cohort 2 - Arm 2 (Type: EXPERIMENTAL): 20 mg
- Cohort 2 - Arm 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutrition, Physical Performance & Fitness in Indian School Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Boys and girls between ages 7-10.5 years~* Z score of height for age and weight for age of 0 to \< -3~* Good general health at screening~* Understands and is willing, able and likely to comply with all study procedures and restrictions~* Written informed consent from the parents/ guardians and writtent assent by the study participant~Exclusion Criteria:~* Severe anemia (Hb\<8 g% )~* Cardiovascular disease on clinical examination or history~* Any underlying respiratory disease with impairment of lung function~* Physical disability Children consuming nutritional supplements (tonics, syrups, tablets or chews) and/ or health food drinks on a regular basis~* Recent history \[3mo\] of serious infections, injuries and/ or surgeries~* Participation in any nutritional study in the last 1 year~* Indication that they are likely to move within the period of study intervention~* Any known food allergies like peanut allergy, gluten allergy~* Family members of an employee of the Sponsor or the study site.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- No intervention (Type: NO_INTERVENTION): No intervention
- Nutritional supplement (Type: EXPERIMENTAL): Fortified nutritional powder
- Placebo (Type: PLACEBO_COMPARATOR): Un-fortified nutritional powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histological diagnosis of well-differentiated neuroendocrine carcinoma according to the World Health Organization (WHO) classification;~* locally advanced or metastatic disease not amenable to surgery with radical intent;~* at least one measurable target lesion;~* radiological documentation of progressive disease;~* ECOG performance status grade \<=2;~* life expectancy \>12 weeks;~* adequate bone marrow reserve;~* adequate hepatic and renal function;~* ability to comply with the protocol procedures (including geographic accessibility);~* written informed consent.~Exclusion Criteria:~* non-malignant systemic disease or conditions that precluded patients from receiving the study therapy;~* second primary malignancies and previous systemic antineoplastic treatment including somatostatin analogues;~* history of prior malignancy, excepted for cured non-melanoma skin cancer, and cured in situ cervical carcinoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): continuous 5 fluouracil infusion plus long-acting octreotide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete